Curriculum Vitae

Adam J. Olszewski, MD Associate Professor of Medicine, Alpert Medical School of Brown University

Address: Lifespan Cancer Institute at Rhode Island Hospital George Building, Rm. 353 593 Eddy St, Providence, RI 02903 Tel: (401) 429 3151 Fax: (401) 444 8918 E-mail: [email protected] ORCID 0000-0002-6472-6658

Language fluency: Spanish, French, Polish, Russian Research profile: https://vivo.brown.edu/display/aolszews

Employment Rhode Island Hospital 02/2016 – present • Clinical Hematologist/Oncologist and researcher Alpert Medical School of Brown University • Assistant Professor of Medicine 08/2010 – 07/2019 • Associate Professor of Medicine 08/2019 – The Cancer Center at Memorial Hospital of Rhode Island 08/2010 – 02/2016 • Clinical Oncologist / Hematologist • Cancer Committee Chair Kent County Hospital, Warwick, RI 2007 – 2010 • Clinical Oncologist / Hematologist • Physician Director, Outpatient Infusion Services University Medical Group, Providence, RI 2006 – 2010 • Clinical Oncologist / Hematologist

Education Hematology/Oncology Fellowship 07/2003 – 06/2006 St. Luke’s-Roosevelt Hospital Center, New York Internal Medicine Residency 07/2000 – 06/2003 St. Luke’s-Roosevelt Hospital Center, New York Teaching affiliate of College of Physicians and Surgeons of Columbia University The Medical University of Warsaw, Poland 09/1993 – 06/1999 MD degree 06/1999

Licensure and certification ABIM Board Certified: Hematology 11/2007 – present ABIM Board Certified: Medical Oncology 11/2006 – present ABIM Board Certified: Internal Medicine 08/2003 – present MD License: Rhode Island 11/2005 – active

Professional affiliations and leadership functions American Society of Clinical Oncology, member American Society of Hematology, member Alpha Omega Alpha Honor Medical Society, member Adam J. Olszewski – CV

Chair, Head and Neck Committee 2015 – 2016 Co-chair, Humanities and Outcomes Committee 2016 – present Brown University Oncology Group (BrUOG) American Society of Clinical Oncology/American Board of Internal Medicine Hematologic Malignancies Test Materials Development Subcommittee 2018 – present Brown University Oncology Group (BrUOG) Member, Data Safety Monitoring Board 2012 – present American Society of Clinical Oncology, Scientific Program Committee Member, Cancer Prevention/Epidemiology Track 2013 – 2016 Track leader 2015 – 2016 American Society of Clinical Oncology, Cancer Education Program Member, Cancer Prevention/Epidemiology Track 2015 – 2016 Chair, Cancer Committee, Memorial Hospital of Rhode Island 2013 – 2016 Member, Institutional Review Board, MHRI 2011 – 2016 Member, Pharmacy and Therapeutics Committee, MHRI 2011 – 2016 Chair, Institutional Review Board, Kent Hospital, Warwick, RI 2007 – 2010 Member, Breast Health Center Leadership Group, Kent Hospital 2009 – 2010

Honors and awards Academic Proficiency Award, years 2 through 6 1994 – 1999 The Medical University of Warsaw, Poland W.I.S.E. (Worldwide Insitute Supporting 1999 Exchange) Scholarship, Worcester, MA Award for Outstanding Excellence in Primary Care 2003 St. Luke’s-Roosevelt Hospital Center, New York Chief Fellow Appointment 2005 St. Luke’s-Roosevelt Hospital Center, New York Teaching Achievement Award for Outstanding Teaching 2014 Internal Medicine Residency Program, Memorial Hospital of Rhode Island, Alpert Medical School of Brown University American Society of Hematology 2015 Scholar Award 2015 (Clinical Junior Faculty) 2015 Beckwith Family Teaching Award for outstanding teaching 2015 Alpert Medical School of Brown University Dean's Excellence in Teaching Award 2015 Alpert Medical School of Brown University American Cancer Society Research Scholar Award 2015 Teaching Achievement Award for Outstanding Teaching 2016 Internal Medicine Residency Program, Memorial Hospital of Rhode Island, Alpert Medical School of Brown University

Excellence in Teaching Award 2019 Hematology-Oncology Fellowship, Alpert Medical School of Brown University

Teaching experience Practice-Based Learning 2011 – 2016 Warren Alpert Medical School of Brown University Clinical Teaching Rounds 2011 – 2013 Memorial Hospital of Rhode Island 2

Adam J. Olszewski – CV

Career Mentorship, Medical Residents PGY1-PGY3 2010 – present Memorial Hospital of Rhode Island Research Mentorship, Brown University Medical Students 2012 – present Internal Medicine Conference Lectures 2011 – present BIOL3672: IMS-IV: Integrated Hematology Course, Faculty 2017 – 2020

Peer-reviewed publications (reverse chronological order) h-index: 15 PubMed bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/adam.olszewski.1/bibliography/40055989/public/

1. Olszewski AJ, Butera JN, Reagan JL, Castillo JJ. Outcomes of bendamustine- or cyclophosphamide- based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2019 Dec 17;. doi: 10.1002/ajh.25707. [Epub ahead of print] PubMed PMID: 31849108. 2. Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Wood WA, Olszewski A, Basch E, Keating NL. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients with Blood Cancers. J Natl Cancer Inst. 2019 Dec 27;. doi: 10.1093/jnci/djz243. [Epub ahead of print] PubMed PMID: 31883008. 3. Olszewski AJ, Barth PM, Reagan JL. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. Cancer Med. 2019 Nov;8(16):6945-6954. doi: 10.1002/cam4.2591. PubMed PMID: 31566898. 4. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner- Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2019. Epub 2019/10/01. doi: 10.1002/cncr.32526. PubMed PMID: 31568564. 5. Decker DP, Egan PC, Zayac AS, Treaba DO, Olszewski AJ. Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma. Leuk Lymphoma. 2020 Jan;61(1):198-201. doi: 10.1080/10428194.2019.1654097. PubMed PMID: 31432717. 6. Ollila TA, Reagan JL, Olszewski AJ. Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. Leuk Lymphoma. 2019 Dec;60(14):3426-3433. doi: 10.1080/10428194.2019.1639166. PubMed PMID: 31287335. 7. Orcutt X, Barth P, Olszewski AJ. Prognostic significance of upfront radiation therapy in patients with multiple myeloma. Am J Hematol. 2019 Jul;94(7):E190-E194. doi.org/10.1002/ajh.25492 PMID: 31006894 8. Olszewski AJ, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera JN, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka PM. Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. Br J Haematol. 2019 Aug;186(3):e31-e35. doi: 10.1111/bjh.15861. PMID: 30859554. 9. Fallah J, Olszewski AJ. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology. 2019;24(1):378-86. PMID: 30885066 10. Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085-94. doi: 10.2147/OTT.S165615. PMID: 30799938 11. Barth P, Castillo JJ, Olszewski AJ. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019;125(4):550-8. doi: 10.1002/cncr.31853. PMID: 30452087. 12. Olszewski AJ, Castillo JJ. Ibrutinib and Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med. 2018;379(20):1973-4. doi: 10.1056/NEJMc1809505. PubMed PMID: 30439672.

3

Adam J. Olszewski – CV

13. Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood. 2018;132(19):2053-66. doi: 10.1182/blood-2018-05- 848408. PubMed PMID: 30213875. 14. Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. J Clin Oncol. 2018;36(28):2879-86. doi: 10.1200/JCO.2018.77.8894. PMID: 30113885 15. LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018 Aug 16;132(7):717-726. doi: 10.1182/blood-2018-03- 842575. 16. Ollila TA, Olszewski AJ. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. Curr Treat Options Oncol. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. 17. Ollila TA, Olszewski AJ. Radiation therapy in primary testicular lymphoma: does practice match the standard of care? Leuk Lymphoma. 2019;60(2):523-6. doi: 10.1080/10428194.2018.1480776. 18. Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol. 2018 May;181(4):495-504. doi: 10.1111/bjh.15224. 19. Olszewski AJ, Zullo AR, Nering CR, Huynh JP. Use of Charity Financial Assistance for Novel Oral Anticancer Agents. J Oncol Pract. 2018 Apr;14(4):e221-e228. doi: 10.1200/jop.2017.027896. 20. Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. Mol Oncol. 2018 May;12(5):630-647. doi: 10.1002/1878-0261.12186. 21. Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018 Jan;93(1):E1-E3. doi: 10.1002/ajh.24921 22. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679-82. doi: 10.1111/bjh.15156. PubMed PMID: 29527667. 23. Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. 24. Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018;59(6):1375-83. doi: 10.1080/10428194.2017.1387912. 25. Olszewski AJ, Chen C, Gutman R, Treon SP, Castillo JJ. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 Oct;179(1):106-115. doi: 10.1111/bjh.14828. 26. Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. J Clin Oncol. 2017 Oct 10;35(29):3306-3314. doi: 10.1200/JCO.2017.72.2447. 27. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157.

4

Adam J. Olszewski – CV

28. Fallah J, Olszewski AJ. Variation in the use of up-front chemotherapy for indolent B-cell lymphomas and chronic lymphocytic leukemia. Hematol Oncol. 2017 Dec;35(4):921-924. doi: 10.1002/hon.2382. 29. Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. Blood Advances. 2016; 1(2):112-121. doi: https://doi.org/10.1182/bloodadvances.2016000927 30. Schumacher A, Sikov WM, Quesenberry MI, Safran H, Khurshid H, Mitchell KM, Olszewski AJ. Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study. PLoS One. 2017;12(2):e0172957. doi: 10.1371/journal.pone.0172957 31. Chorzalska A, Flores Kim J, Roder K, Tepper A, Ahsan N, Rao RS, Olszewski AJ, Yu X, Terentyev D, Morgan J, Treaba DO, Zhao T, Liang O, Gruppuso P, Dubielecka P. Long-term exposure to imatinib mesylate downregulates Hippo pathway and activates YAP in a model of chronic myelogenous leukemia. Stem Cells Dev. 2017 May 1;26(9):656-677. doi: 10.1089/scd.2016.0262. 32. Olszewski AJ. Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma. Leuk Lymphoma. 2017 May;58(5):1013-1015. doi: 10.1080/10428194.2016.1262035. 33. Olszewski AJ, Treon SP, Castillo JJ. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A population-based Analysis. Oncologist. 2016; 21(11):1377-1386. doi: theoncologist.2016-0126 34. Olszewski AJ, Gutman R, Eaton CB. Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. Haematologica. 2016 Dec;101(12):e488-e491. doi:10.3324/haematol.2016.148858 35. Mantripragada KC, Hamid F, Shafqat H, Olszewski AJ. Adjuvant therapy for resected gallbladder cancer: analysis of the National Cancer Data Base. J Natl Cancer Inst. 2017 Feb;109(2). doi: 10.1093/jnci/djw202 36. Olszewski AJ, Mantripragada KC, Castillo JJ. Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma. J Natl Compr Canc Netw. 2016 Sep;14(9):1121-9. 37. Olszewski AJ. Formulating a novel prognostic index for diffuse large B-cell lymphoma: T-cells break the SILence. Leuk Lymphoma. 2016 Dec;57(12):2733-2735. doi: 10.1080/10428194.2016.1220009 38. Olszewski AJ, Fallah J, Castillo JJ. HIV-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. Cancer. 2016 Sep 1;122(17):2689-97. doi: 10.1002/cncr.30112 39. Mantripragada KC, Olszewski AJ, …, Safran H. Clinical Trial Accrual Targeting Genomic Alterations Following Next Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. J Oncol Pract. 2016 Apr;12(4):e396-404. doi: 10.1200/JOP.2015.008433. 40. Olszewski AJ, Fallah J, Castillo JJ. Survival claims from observational data on cancer therapy. J Clin Oncol. 2016 Apr 20;34(12):1425-7. doi: 10.1200/jco.2015.64.7644. 41. Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy: analysis of the National Cancer Data Base. AIDS. 2016 Mar 13;30(5):787-96. doi: 10.1097/QAD.0000000000000986 42. Olszewski AJ. Limits of registry data to understand survival disparities in lymphoma. Lancet Haematol. 2015 Nov;2(11):e459-60. doi: 10.1016/S2352-3026(15)00188-X. 43. Olszewski AJ, Foran JM. Health Insurance-Related Disparities in Lymphoma Survival Are Partly Mediated by Baseline Clinical Factors. Oncologist. 2015 Oct;20(10):1223-4. doi: 10.1634/theoncologist.2015-0228. 44. Migdady Y, Salhab M, Dang NH, Markham MJ, Olszewski AJ. Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. Leuk Lymphoma. 2016;57(3):676-84. doi: 10.3109/10428194.2015.1102246. 45. Olszewski AJ, Shrestha R, Cook NM. Race-specific features and outcomes of nodular lymphocyte- predominant Hodgkin lymphoma: analysis of the National Cancer Data Base. Cancer. 2015 Oct 1;121(19):3472-80. doi: 10.1002/cncr.29527.

5

Adam J. Olszewski – CV

46. Khan H, Khan N, Ahmad A, Olszewski AJ, Somasundar P. Surgical management of metastatic colon cancer: A population-based analysis. J Geriatr Oncol. 2015 Nov;6(6):446-53. doi: 10.1016/j.jgo.2015.08.002 47. Olszewski AJ, Ali S, Witherby SM. Disparate survival trends in histologic subtypes of metastatic non- small cell lung cancer: a population-based analysis. Am J Cancer Res 2015;5(7):2229-2240. http://www.ajcr.us/files/ajcr0007771.pdf 48. Fallah J, Afari ME, Cordova AC, Olszewski AJ, Minami T. Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. Case Rep Oncol Med. 2015;2015:865383. doi: 10.1155/2015/865383. 49. Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug;26(8):1163-72. doi: 10.1007/s10552-015-0610-8. 50. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Survival outcomes of secondary cancers in patients with Waldenström Macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug;90(8):696-701. doi: 10.1002/ajh.24052 51. Castillo JJ, Olszewski AJ, Hunter ZR, Kanan S, Meid K, Treon SP. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. Cancer. 2015 Jul 1;121(13):2230-6. doi: 10.1002/cncr.29334 52. Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the national cancer data base. J Clin Oncol. 2015 Feb 20;33(6):625-33. doi: 10.1200/JCO.2014.58.7543. 53. Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015 Mar;58(3):294-303. doi: 10.1097/DCR.0000000000000298. 54. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr;169(1):81-9. doi: 10.1111/bjh.13264. 55. Olszewski AJ, Shafqat H, Ali S. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. Leuk Lymphoma. 2015 Apr;56(4):942-50. doi:10.3109/10428194.2014.936013 56. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19;123(25):3999-4000. doi: 10.1182/blood-2014-05-574871. 57. Khan H, Olszewski AJ, Somasundar P. Lymph node involvement in colon cancer patients decreases with age; A population based analysis. Eur J Surg Oncol. 2014 Nov;40(11):1474-80. doi: 10.1016/j.ejso.2014.06.002. 58. Olszewski AJ, Winer ES, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014 Aug;38(8):866-73. doi: 10.1016/j.leukres.2014.04.009. 59. Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D, Schorl C, Morgan J, Bryke CR, Falanga V, Zhao TC, Reagan J, Winer E, Olszewski AJ, Al-Homsi S, Kouttab N, Dubielecka PM. Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia. 2014 Nov;28(11):2165-77. doi: 10.1038/leu.2014.120. 60. Olszewski AJ, Desai A. Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. Int J Radiat Oncol Biol Phys. 2014;88(3):642-649. doi: 10.1016/j.ijrobp.2013.11.225 61. Shafqat H, Olszewski AJ. Chlorambucil-induced acute interstitial pneumonitis. Case Rep Hematol. 2014;2014:575417. doi: 10.1155/2014/575417. 62. Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2014;93(3):449-458. doi: 10.1007/s00277-013-1900-4

6

Adam J. Olszewski – CV

63. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. Am J Hematol. 2014;89(3):310-314. doi: 10.1002/ajh.23638. 64. Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis. Int J Cancer. 2014;134(12):2961-2971. doi: 10.1002/ijc.28625. 65. Ali S, Olszewski AJ. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study. Leuk Lymphoma. 2014 Jul;55(7):1570-7. doi:10.3109/10428194.2013.847938 66. Shafqat H, Alquadan KF, Olszewski AJ. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. Osteoporos Int. 2014;25(3):1187-1190. doi: 10.1007/s00198-013-2533-0 67. Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol. 2013 May;24(5):1352- 9. doi: 10.1093/annonc/mds644 68. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119(20):3672-3679. doi: 10.1002/cncr.28264 69. Olszewski AJ, Migdady Y, Boolbol S, Klein P, Boachie-Adjei K, Sakr B, et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Res Treat. 2013 Feb;138(1):215-23. doi: 10.1007/s10549-013- 2423-3 70. Migdady Y, Sakr BJ, Sikov WM, Olszewski AJ. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes. Breast. 2013;22(5):793-798. doi: 10.1016/j.breast.2013.02.014. 71. Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G- FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2 72. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119(3):629-38. doi: 10.1002/cncr.27773. 73. Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol. 2012 Nov;87(11):E119-22. doi: 10.1002/ajh.23314. 74. Desai A, Telang GH, Olszewski AJ. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Ann Hematol. 2013 Apr;92(4):567-8. DOI: 10.1007/s00277- 012-1610-3. 75. Migdady Y, Olszewski AJ. Evaluation of incidental neutropenia in a multi-ethnic setting. Int J Lab Hematol. 2013 Feb;35(1):e6-8. DOI: 10.1111/ijlh.12016. 76. Gavini A, Telang G, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. Int J Hematol. 2012 Mar;95(3):311-4. DOI: 10.1007/s12185-012-1012-2. 77. Casey DJ, Kim AY, Olszewski AJ. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. Am J Hematol. 2012 May;87(5):521-4.. DOI: 10.1002/ajh.22239 78. Migdady Y, Olszewski AJ. Paroxysmal Nocturnal Hemoglobinuria Presenting with a Left Intraventricular Thrombus in a Patient with Prior Thymoma and Aplastic Anemia. Clinical Medicine Insights: Oncology 2011:5 343-348. doi: 10.4137/CMO.S8442 79. Olszewski AJ, Grossbard ML, Kozuch P. The Horizon of Antiangiogenic Therapy for Colorectal Cancer. Oncology (Williston Park). 2005 Mar;19(3):297-306. 80. Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from rituximab. Science STKE. 2004 Jul 6;2004(241):PE30. 81. Olszewski AJ, Shapiro JM. Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection. J Intensive Care Med. 2003 May-Jun;18(3):156-9.

7

Adam J. Olszewski – CV

82. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000 Apr 14;288(5464):335-9. DOI: 10.1126/science.288.5464.335

Book chapters and other publications Ferri F (ed.). Ferri's Clinical Advisor 2017, 1st Edition. Elsevier, 2016, ISBN 9780323280488. (Contributor, chapters “Leukemia: Chronic Lymphocytic”, “Leukemia: Hairy Cell”). Ferri F (ed.). Ferri's Clinical Advisor 2018, 1st Edition. Elsevier, 2017, ISBN-13: 978-0323280495. (Contributor, chapters “Leukemia: Chronic Lymphocytic”, “Leukemia: Hairy Cell”). Ferri F (ed.). Ferri's Clinical Advisor 2019, 1st Edition. Elsevier, 2018, ISBN-13: 978-0323530422. (Contributor, chapters “Leukemia: Chronic Lymphocytic”, “Leukemia: Hairy Cell”).

Abstracts and research presentations 1. Olszewski AJ, Davids MS, Yakirevich I, Egan PC. Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation. 2. Rao VB, Belanger E, Egan PC, LeBlanc TW, Olszewski AJ. Rao V, Olszewski AJ, Egan PC, LeBlanc TW, Belanger E. Billed palliative care services and end-of-life care in patients with hematologic malignancies. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation. 3. Zayac A, Evens AM (…, 50 authors), Lossos IS, Olszewski AJ. Outcomes of Patients with Newly- Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation. 4. Evens AM, Danilov A (…, 50 authors), Olszewski AJ, Alderuccio JP. The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation. 5. Olszewski AJ, Ollila TA, Reagan JL. Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 6. Olszewski AJ, Chorzalska AD, Treaba DO, Reagan JL, Egan PC, Kurt H, Butera J, Rafelson W, Mohler AC, Ollila TA, Niroula R, Robison J, Mullins CD, Dubielecka PM. Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 7. Barth P, Giri S, Reagan JL, Olszewski AJ. Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 8. Giri S, Barth P, Costa LJ, Olszewski AJ. Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 9. Rhodes JM, Sundaram S, Zayac A, Olszewski AJ, Caimi P, Braunstein Z, Brammer JE, Jehangir W, Umyarova E, Sheela S, Ghosh N, Nasta SD, Barta SK. Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA). 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 10. Di M, Ollila TA, Olszewski AJ. Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.

8

Adam J. Olszewski – CV

11. Di M, Olszewski AJ. Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 12. Zayac A, Egan PC, Ollila TA, Olszewski AJ, Barth P, Quesenberry MI, Butera J, Fast LD, Niroula R, Quesenberry PJ, Reagan JL. Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 13. Mao C, Olszewski AJ, Egan PC, Barth P, Reagan JL. Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation. 14. Rao V, Olszewski AJ, Egan PC, LeBlanc TW, Belanger E. Billed palliative care services and end-of- life care in patients with hematologic malignancies. 2019 Supportive Care in Oncology Symposium. San Francisco, CA, October 26, 2019-oral presentation at a non-plenary session. 15. Olszewski AJ, Barth P, Giri S, Reagan J. Comparative effectiveness of lenalidomide, bortezomib, and their combination as fist-line treatment of older patients with myeloma. 17th International Myeloma Workshop, Boston, MA, September 12-15, 2019—oral presentation. 16. Olszewski AJ, Ollila T, Reagan JL. Rituximab alone (R) versus rituximab plus bendamustine (BR) for splenic (SMZL) and nodal marginal zone lymphoma (NMZL). Hematological Oncology. 2019;37(S2):225-6. doi: 10.1002/hon.40_2630. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019—poster presentation. 17. Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D'Sa S, Kersten M, Palomba M, Spearing R, Thomas S, Olszewski AJ, Scott C, Harrington C, Trotman J. WhiMSICAL (Waldenström's macroglobulinemia study involving cart-wheel): a global patient-derived data registry mapping treatment and quality of life. Hematological Oncology. 2019;37(S2):234-5. doi: 10.1002/hon.46_2630. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019—poster presentation. 18. Budde LE, Vallurupalli A, Babu S, Lossos IS, Alderuccio JP, Chavez JC, Eradat H, Holmes H, Hamadani M, Karur VG, Olszewski AJ, Seymour E, Althaus B, Medeiros BM, Li CC, Kwan A, Wei MC, Yin S, O'Hear C, Munoz J. Ongoing phase 1b/2 trials of mosunetuzumab investigating novel treatment regimens for patients with B-cell non-Hodgkin lymphoma (NHL). Hematological Oncology. 2019;37(S2):564-6. doi: 10.1002/hon.12_2632. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019—poster presentation. 19. Olszewski AJ, Barth P, Reagan JL. Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 709)—oral presentation. 20. Di M, Olszewski AJ. Adjuvant Chemotherapy Administration and Survival Outcomes in Lymphoma Survivors with Common Solid Tumors: A Population-Based Study. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 621)—oral presentation. 21. Egan PC, LeBlanc TW, Olszewski AJ. End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 829)—oral presentation. 22. Olszewski AJ, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera J, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka P. Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 3841)—poster presentation. 23. Ollila TA, Reagan JL, Olszewski AJ. Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1- 4, 2018 (Abs 2913)—poster presentation. 24. Decker D, Egan PC, Treaba DO, Olszewski AJ. Survival and Risk of Central Nervous System Recurrence in Burkitt or High-Grade B-Cell Lymphoma in the DA-EPOCH-R Era. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 2983)—poster presentation.

9

Adam J. Olszewski – CV

25. Orcutt X, Barth P, Olszewski AJ. Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 3230)—poster presentation. 26. Ollila TA, Zayac A, Olszewski AJ, Hilliard RW, Riley D, Pelcovits A, Austin MR, Keane M, Reagan JL. Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 2442)—poster presentation. 27. Chorzalska AD, Morgan J, Petersen M, Treaba DO, Olszewski AJ, Reagan JL, Dubielecka P. Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 1285)— poster presentation. 28. Kothari SK, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess BT, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee SS, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 451)—oral presentation. 29. Ayers EC, Li S, Medeiros J, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy N, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach C, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline S, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 453)—oral presentation. 30. Olszewski AJ, Egan P, Decker D, Treaba D. Survival Outcomes and Risk of Central Nervous System (CNS) Recurrence in Burkitt (BL) or High-Grade B-Cell Lymphoma (HGBCL) in the DA-EPOCH-R Era. European School of Haematology (ESH) 4th Annual International Conference on New Concepts in Lymphoid Malignancies, Saggart (Dublin), Ireland, September 28-30th, 2018—poster presentation. 31. Olszewski AJ, Egan P, LeBlanc TW. Hospice use among Medicare fee-for-service (FFS) or managed- care organization (MCO) enrollees with leukemia and myeloma. 2018 ASCO Annual Meeting, Chicago, IL. June 4, 2018 (Abs 10025)—poster presentation. 32. Ollila T, Olszewski AJ. Radiation therapy in primary testicular lymphoma (PTL): Does practice match the standard of care? 2018 ASCO Annual Meeting, Chicago, IL. June 4, 2018 (Abs 7544)—poster presentation. 33. Olszewski AJ, Treon SP, Castillo JJ. Application and Outcomes of Bendamustine- or Bortezomib- Based Therapy for Waldenstrom’s Macroglobulinemia. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 348)—oral presentation. 34. Olszewski AJ, Egan PC, LeBlanc TW. Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 277)—oral presentation. 35. Guerrero T, Bibas M, Baldini F, Cartron C, Cwynarski K, Dierickx D, Lansingan F, Linnik YA, Mogollon R, Navarro JT, Ninkovic S, Olszewski AJ¸ Reagan JL, Tchernonog E, Tousseyn T, Castillo JJ. Use of Bortezomib-Containing Regimens in the Frontline Treatment of Patients with Plasmablastic Lymphoma: A Multicenter Retrospective Analysis. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 1580)—poster presentation. 36. Chorzalska AD, Morgan J, Treaba DO, Olszewski AJ, Lombardo K, Zini R, Pacillli A, Tepper A, Reagan JL, Kotula L, Quesenberry PJ, Gruppuso P, Manfredini R, Vannucchi AM, Dubielecka P. Beyond JAK- STAT: Contribution of Abi-1, STAT3, and NF-κb Signaling to Pathogenesis of Myeloproliferative Neoplasms. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 4210)— poster presentation.

10

Adam J. Olszewski – CV

37. Chorzalska AD, Ahsan N, Tepper A, Hines S, Treaba DO, Olszewski AJ, Reagan JL, Gruppuso P, Dubielecka P. Map3k8/COT1/Tpl2 Drives Resistance to Bcr-Abl1 Inhibition through Activation of MEK- ERK and NF-Kb Pathways. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 2529)—poster presentation. 38. Ollila T, Olszewski AJ, Quesenberry PJ, Quesenberry MI, Butera J, Reagan HL. Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 1428)— poster presentation. 39. Leblanc TW, Olszewski AJ. Use of hospice services among Medicare beneficiaries with acute and chronic leukemias. 2017 ASCO Palliative and Supportive Care in Oncology Symposium; San Diego, CA, October 27-28, 2017 (Abs 68)—poster presentation. 40. Olszewski AJ, Castillo JJ. Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis. 14th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 14-17, 2017 (Abs 222)—poster presentation. 41. Olszewski AJ, Dusetzina S, Davidoff AJ, Trivedi AN. Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents. 2017 ASCO Annual Meeting, Chicago, IL. June 2-6, 2017 (Abs 6522)—poster presentation. 42. Castillo JJ, Olszewski AJ. Outcomes of secondary cancers among myeloma survivors. 2017 ASCO Annual Meeting, Chicago, IL. June 2-6, 2017 (Abs 8043)—poster presentation. 43. Khudayar H, Fallah J, Souaid R, Olszewski AJ. Mammography use, incidence, and survival of primary breast lymphoma. 2017 ASCO Annual Meeting, Chicago, IL. June 2-6, 2017 (Abs e13087). 44. Olszewski AJ, Eaton CB, Trivedi AN. Association of Medicare Part D Coverage and Low-Income Subsidies with Use of Novel Oral Agents in Multiple Myeloma. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 686)—oral presentation. 45. Olszewski AJ, Treon SP, Castillo JJ. Comparative Effectiveness of Rituximab-Based Immunochemotherapy in Waldenstrom’s Macroglobulinemia. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 2986)—poster presentation. 46. Qunaj L, Castillo JJ, Olszewski AJ. CD20-Negative Large B-Cell Lymphomas: Analysis of the National Cancer Data Base. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 4226)—poster presentation. 47. Fallah J, Olszewski AJ. Variation in the Use of Splenectomy for Splenic Lymphomas: Analysis of the National Cancer Data Base.58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 3584)—poster presentation. 48. Reagan JL, Ollila T, Dubielecka PM, Olszewski AJ. Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 1994)—poster presentation. 49. Chorzalska AD, Morgan J, Treaba DO, Olszewski AJ, ..., Dubielecka PM. Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFκB. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 1203)—oral presentation. 50. Mantripragada KC, Hamid F, Olszewski AJ. Adjuvant therapy for gallbladder carcinoma (GBCA): Analysis of the National Cancer Data Base (NCDB). 2016 ASCO Annual Meeting, Chicago, IL. June 2016 (Abs. 4082)—poster presentation. 51. Qunaj L, Fallah J, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma (PCSNL) in the United States: Analysis of the National Cancer Data Base (NCDB). 2016 ASCO Annual Meeting, Chicago, IL. June 2016 (Abs. 2026)—poster presentation. 52. Fallah J, Olszewski AJ. Variation in the administration of early chemotherapy for indolent lymphomas: Analysis of the National Cancer Data Base (NCDB). 2016 ASCO Annual Meeting, Chicago, IL. June 2016 (Abs. e18005)—electronic abstract. 53. Hamid F, Shafqat H, Matripragada K, Guerrero T, Somadundar P, Olszewski AJ. Outcomes of multimodality therapy for gallbladder cancer in the United States (US): Analysis of the National Cancer Data Base (NCDB). ASCO 2016 Gastrointestinal Cancers Symposium—poster presentation.

11

Adam J. Olszewski – CV

54. Olszewski AJ, Gutman R, Eaton CB. Increased Fracture Risk in Patients with Untreated Chronic Lymphocytic Leukemia (CLL): A Population-Based Analysis. 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—oral presentation (abstract #878). 55. Olszewski AJ, Fallah J, Eaton CB, Treon SP, Castillo JJ. The Evolution of Management and Survival Outcomes of Waldenström Macroglobulinemia (WM) in the United States (US). 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—oral presentation (abstract #882). 56. Olszewski AJ, Castillo JJ. Prognosis of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #3861). 57. Fallah J, Thomas AG, Olszewski AJ. Watchful Waiting As Initial Management of Advanced-Stage Follicular Lymphoma in the Rituximab Era: Analysis of the National Cancer Data Base. 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #2692). 58. Chorzalska A, Kim JF, Roder K, Olszewski AJ, Terentyev D, Dubielecka PM. Downregulation of Mir- 181a Restores Chemosensitivity to Imatinib Mesylate in Chronic Myeloid Leukemia Cells Resistant to Tyrosine Kinase Inhibitors. 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL— poster presentation (abstract #4016). 59. Matripragada K, Castillo JJ, Olszewski AJ. Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL). 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #3914). 60. Olszewski AJ, Castillo JJ. Management of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). 2015 ASH Meeting on Hematologic Malignancies, Chicago IL. September 2015—oral presentation. 61. Fallah J, Thomas AG, Olszewski AJ. Abbreviated Chemotherapy and Radiation for Early-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the R-CHOP Era: Analysis of the National Cancer Data Base (NCDB). 2015 ASH Meeting on Hematologic Malignancies, Chicago IL. September 2015—oral presentation. 62. Olszewski AJ, Mantripragada K, Castillo JJ. Risk Factors for Early Death after Rituximab-Based Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL). 2015 ASH Meeting on Hematologic Malignancies, Chicago IL. September 2015 (Abs. 48)—poster presentation. 63. Olszewski AJ, Fallah J, Castillo JJ. Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL) in the United States (US): Analysis of the National Cancer Data Base (NCDB). 2015 ASCO Annual Meeting, Chicago, IL. May 2015 (Abs. 1521)—poster presentation. 64. Saleh MN, Sakr BJ, Witherby SM, Olszewski AJ, Sikov WM. Breast cancer recurrence in older patients with clinically node-negative T1-T2 tumors managed without sentinel node biopsy (SNB) and without adjuvant radiation therapy. 2015 ASCO Annual Meeting, Chicago, IL. May 2015 (Abs. 528)—poster presentation. 65. Ahmad A, Khan H, Olszewski AJ, Somasundar P. Nodal Involvement in Gastric Adenocarcinoma Decreases with Age: A Population-based Analysis. SSO 68th Annual Cancer Symposium. Houston, TX, March 25-29, 2015—poster presentation (Abs. P364). 66. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter Z, Treon SP. Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia. 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014—oral presentation (abs. 855). 67. Shrestha R, Cook NM, Olszewski AJ. Race-Specific Features and Treatment Patterns of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) in the United States: Analysis of the National Cancer Data Base. 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014—poster presentation (abs. 2594). 68. Olszewski AJ. Utility of the International Prognostic Index (IPI), Revised IPI and a Model-Based Score for Risk Stratification of Diffuse Large B-Cell Lymphoma (DLBCL) in the National Cancer Data Base (NCDB). 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014—poster presentation (abs. 1308).

12

Adam J. Olszewski – CV

69. Olszewski AJ, Ali S, Witherby SM. Survival trends in histologic subtypes of metastatic non-small cell lung cancer (mNSCLC) in the United States: 2000-2010. The ASTRO, ASCO and IASLC 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. October 30 – November 1, 2014, Chicago, IL. Published in: Int J Radiat Oncol Biol Phys 90: S57-S58. 70. Chorzalska A, Salloum I, Treaba D, Schorl C, Morgan J, Bryke C, Reagan J, Wine E, Olszewski AJ, Dubielecka P. New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance. 43rd Annual Scientific Meeting of the ISEH – International Society for Experimental Hematology. 21-24 August, 2014, Montreal, Canada (Abs.1034)—poster presentation. Published in: Experimental Hematology. 2014 Aug;42(8);S31. 71. Shrestha R, Castillo JJ, Olszewski AJ. Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma: A comparative, population-based study. ASCO 2014 50th Annual Meeting, Chicago, IL. May 2014 (Abs. 125495)—poster presentation. 72. Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of high-grade neuroendocrine carcinomas (HGNEC) of the colon and rectum: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. ASCO 2014 50th Annual Meeting, Chicago, IL. May 2014 (Abs. 125582)—poster presentation. 73. Chorzalska A, Schorl C, Dubielecka P, Salloum I, Morgan J, Treaba D, Winer ES, Reagan JL, Olszewski AJ. Cellular level of Abelson interactor-1 as a marker predicting chemoresistance. ASCO 2014 50th Annual Meeting, Chicago, IL. May 2014 (Abs. 135188)—poster presentation. 74. Khan H, Olszewski AJ, Somasundar P. Surgical Management of Metastatic Colon Cancer in Elderly: Analysis of the Surveillance, Epidemiology and End Results (SEER) Database. Fourteenth Annual Americas Hepato-Pancreato-Biliary Congress 19-23 February 2014, Miami Beach, FL, USA—oral presentation. 75. Khan H, Somasundar P, Olszewski AJ. Nodal involvement and impact of adequate staging in older patients with resectable colon cancer: A population-based analysis. J Clin Oncol 32, 2014 (suppl 3; abstr 424). 2014 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 16-18 January, 2014—poster presentation. 76. Olszewski AJ, Ali S, Shafqat H. Survival After Rituximab-Based Chemoimmunotherapy In Older Patients With Follicular, Nodal Marginal Zone and Small Lymphocytic Lymphoma: Analysis Of SEER- Medicare Data. Blood 2013 122:1736. ASH Annual Meeting, New Orleans, LA. December 2013— poster presentation. 77. Migdady Y, Salhab M, Olszewski AJ. Living In Remission: Disparities In Conditional Survival Among Non-Hodgkin Lymphoma Survivors. Blood 2013 122:2915. ASH Annual Meeting, New Orleans, LA. December 2013—poster presentation. 78. Desai A, Olszewski AJ. Evaluation of the physician-patient communication assessment tool (CAT) in a hematology-oncology practice. J Clin Oncol 31, 2013 (suppl 31; abstr 14)—2013 ASCO Quality Care Symposium, San Diego, CA, November 2013—poster presentation. 79. Olszewski AJ. Comparative outcomes of splenectomy and rituximab-based chemotherapy in elderly patients with splenic marginal zone lymphoma. J Clin Oncol 31, 2013 (suppl; abstr 8549) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation. 80. Ali S, Olszewski AJ. Nodular lymphocyte-predominant and classical Hodgkin lymphoma subtypes: Differences in biology, survival, and impact of radiotherapy. J Clin Oncol 31, 2013 (suppl; abstr 8550) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation. 81. Bishop K, Olszewski AJ. Melanoma of ocular, mucosal, and genital sites: Epidemiology and survival outcomes. J Clin Oncol 31, 2013 (suppl; abstr 9051) ASCO 49th Annual Meeting 2013, Chicago, IL — poster presentation. 82. Taber AM, Khurshid H, Perez K, Birnbaum AE, Olszewski AJ, Luppe D, Jean M, Rosati K, Safran H. Phase I study of ridaforolimus with cetuximab for patients with advanced non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer. J Clin Oncol 31, 2013 (suppl; abstr 8075) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation. 83. Austin TC, Perez K, Fontes-Borts L, Luppe D, Jean M, Olszewski AJ, Rosati K, Rathore B, Safran H. A phase II study of cabazitaxel in patients with previously treated metastatic gastroesophageal adenocarcinoma. J Clin Oncol 31, 2013 (suppl; abstr e15095) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation. 13

Adam J. Olszewski – CV

84. Shao T, Olszewski AJ, Boolbol SK, Migdady Y, Boachie-Adjei K, Sakr BJ, Klein P, Sikov W. Disease- related outcomes with adjuvant chemotherapy in HER2 positive or triple negative T1a/bN0 breast cancers. SABCS 2012, Abstr. P6-07-34. doi: 10.1158/0008-5472.SABCS12-P6-07-34—poster presentation. 85. Olszewski AJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: Analysis of the surveillance, epidemiology and, end results (SEER)-Medicare database. ASCO 2013 Gastrointestinal Cancers Symposium, Abstr.75—poster presentation. 86. Perez K, Pricolo V, Vrees M, Dipetrillo T, Oldenberg N, Klipfel A, Schecter S, Kinsella T, Roth L, Cataldo T, Shah N, Olszewski A, Isdale D, Safran H, Sikov W: A Phase II Study of Complete Neoadjuvant Therapy in Rectal Cancer (CONTRE): The Brown University Oncology Group. ASCO 2013 Gastrointestinal Cancers Symposium, Abstr.335)—poster presentation. 87. Desai A, Kuritzky B, Castillo JJ, Olszewski AJ: Vertebral Compression Fractures in Patients with Chronic Lymphocytic Leukemia: Incidence and Risk Factors. ASH Annual Meeting, Abstr 4586. 88. Olszewski AJ, Desai A: Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. ASH Annual Meeting 2012, Abstr. 2053—poster presentation. 89. Olszewski AJ. Survival with splenectomy in splenic marginal zone lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. J Clin Oncol 30, 2012 (suppl; abstr 8044), ASCO 48th Annual Meeting 2012, Chicago, IL —poster presentation. 90. Castillo JJ, Olszewski AJ. Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. J Clin Oncol 30, 2012 (suppl; abstr 8045), ASCO 48th Annual Meeting 2012, Chicago, IL —poster presentation. 91. Migdady Y, Sikov WM, Sakr BJ, Olszewski AJ. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. J Clin Oncol 30, 2012 (suppl; abstr 1034), ASCO 48th Annual Meeting 2012, Chicago, IL—poster presentation. 92. Olszewski AJ, Malamud S, Grossbard ML, Mirzoyev T, Dietrich M, Thurakal A, Rodriguez T, Kozuch P. Phase I dose-finding study of biweekly oxaliplatin (E) in combination with gemcitabine (G), 5- fluorouracil (5-FU), leucovorin (LV) and irinotecan (G-FLIE) in patients with solid tumors. Proc ASCO 2005: Abs#4202.

Invited presentations 1. “Estimating Treatment Effects from secondary data: novel therapies in hematological malignancies” – Population Science Group Seminar, July 10, 2019; Brown University, Providence, RI. 2. Olszewski AJ. "Aggressive B-cell non-Hodgkin lymphoma" - 2019 New England Lymphoma Workshop, Boston, MA. March 23, 2019. 3. “Is there a standard of care for treatment-naïve Waldenström macroglobulinemia?” – Keynote speaker. 10th International Workshop on Waldenström’s Macroglobulinemia (IWWM10), October 11-14, 2018, New York City, NY, USA 4. Olszewski AJ. "Aggressive B-cell non-Hodgkin lymphoma" - 2018 New England Lymphoma Workshop, Boston, MA. April 28, 2018. 5. “Using big data to address disparities in access to cancer therapy”.3rd Annual Rhode Island Research Breakfast. American Cancer Society, October 14, 2016. (The Hope Club, Providence, RI). 6. “Updates in Hematology/Oncology-Immunotherapy”, Grand Rounds at the Department of Medicine, Memorial Hospital of Rhode Island. January 27, 2016. Pawtucket, RI. 7. “The promise and perils of using population registries for assessment of treatment in oncology” Grand Rounds at the Division of Hematology-Oncology, Rhode Island Hospital. October 15, 2015. Providence, RI. 8. “Emergent treatments for lymphomas: new opportunities and challenges”, Grand Rounds at the Department of Medicine, Memorial Hospital of Rhode Island. October 1, 2014. Pawtucket, RI. 9. “Care of the cancer survivors”, Grand Rounds at the Department of Family Medicine, Memorial Hospital of Rhode Island. May 7, 2014. Pawtucket, RI. 14

Adam J. Olszewski – CV

10. “Using big data for assessment of treatment effects in oncology”, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, May 5, 2014. Boston, MA. 11. “Management of chronic lymphocytic leukemia, 2014 update”, Roger William Medical Center, March 11, 2014. Providence, RI. 12. “Causal inference in observational studies – a practical approach”, Grand Rounds at The Brown University Center of Primary Care and Prevention. April 10, 2013. Pawtucket, RI. 13. “Latinos Hablemos Claro sobre Cancer”. 5th Annual Latino Cancer Control Task Force Conference, October 20, 2010. Providence, RI

Other presentations Ollila T, Olszewski AJ. Early Unfavorable Hodgkin Lymphoma in the era of bleomycin shortage. New England Lymphoma Rounds. Lymphoma Research Foundation. November 16, 2016. Boston, MA. Saleh MN, Sakr BJ, Witherby SM, Olszewski AJ, Sikov WM. Breast cancer recurrence in older patients with clinically node-negative T1-T2 tumors managed without sentinel node biopsy (SNB) and without adjuvant radiation therapy. 21st Annual Research Forum. Warren Alpert Medical School Department of Medicine. June 29, 2015. Providence, RI Shrestha R, Castillo JJ, Olszewski AJ. “Chemotherapy or Combined Modality Therapy for Early-Stage Hodgkin Lymphoma: A Comparative, Population-Based Study”. 20th Annual Research Forum. Warren Alpert Medical School Department of Medicine. June 12, 2014. Providence, RI Ali S, Olszewski AJ. “Nodular Lymphocyte-Predominant and Classical Hodgkin Lymphoma Subtypes: Differences in Incidence, Survival, and Rates of Secondary Malignancy” Public Health Research Day at Brown University, April 18, 2013. “Nodular Lymphocyte Predominant Hodgkin Lymphoma”. New England Lymphoma Rounds. Lymphoma Research Foundation. November 7, 2012. Providence, RI. “Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer”. 18th Annual Research Forum. Warren Alpert Medical School Department of Medicine. June 18, 2012. Providence, RI “The Ever Changing Follicular Lymphoma”. New England Lymphoma Rounds. Lymphoma Research Foundation. November 9, 2011. Providence, RI. “Paroxysmal Nocturnal Hemoglobulinuria Presenting as a Ventricular Mass – A Late Complication Of Prior Aplastic Anemia and Thymoma”. Migdady, Y., Olszewski, AJ. Kenney Research Day, Memorial Hospital of Rhode Island. March 25, 2011

Voluntary activities Ad hoc reviewer: • New England Journal of Medicine 2018 • Journal of Clinical Oncology 2015-2019 • Clinical Cancer Resarch 2017-2019 • Annals of Oncology 2012-2017 • British Journal of Haematology 2013-2019 • International Journal of Cancer 2013-2019 • International Journal of Radiation Oncology, Biology & Physics 2015-2019 • AIDS 2018 • Cancer Epidemiology Biomarkers & Prevention 2015-2019 • Journal of Translational Medicine 2018 • Osteoporosis International 2018 • BMC Cancer 2015-2018 • Journal of Gastrointestinal Cancer 2012, 2016 • BMC Hematology 2013 • Blood and Lymphatic Cancer: Targets and Therapy 2014 • Colorectal Disease 2015 15

Adam J. Olszewski – CV

• International Journal for Quality in Health Care 2015 • Hematological Oncology 2015 • Leukemia & Lymphoma 2015-2017 • Lancet Haematology 2015 • CA: A Cancer Journal for Clinicians 2015 • Oncotarget 2016 • Blood 2016 • BMJ Open 2016-2017 • Future Oncology 2017 • Mediterranean Journal of Hematology and Infectious Diseases 2017 • PLoS ONE 2017 • European Journal of Haematology 2017 • Mayo Clinic Proceedings 2017 • Cancer 2017 • Cancer Medicine 2017 • Breast Cancer Research and Treatment 2012 • Lymphoma Research Foundation, New England Lymphoma Rounds Steering Committee, member 2017 • American Society of Hematology, Basic/Translational Science Scholar Award 2019 Study Section Grant Panel • American Society of Clinical Oncology Workforce Advisory Group, member 2017-2019 • American Society of Clinical Oncology Taxonomy Task Force, member 2016 • Health Policy and Health Services grant peer review committee, American Cancer Society Ad hoc member 2015-2017 Standing member 2018-2020 • Chair, Cancer Prevention, Genetics and Epidemiology Poster Discussion Session 2016 ASCO 2016 Annual Meeting, Chicago, IL. June 2016 • Co-chair, Clinical Science Symposium 2015 “A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing Results Together” ASCO 2015 Annual Meeting, Chicago, IL. May 2015 • Co-chair, Cancer Prevention/Epidemiology Oral Abstract Session 2015 ASCO 2015 Annual Meeting, Chicago, IL. May 2015 • Chair, Clinical Science Symposium 2014 “Next-Generation Sequencing Panels for Cancer Risk Assessment”. ASCO 2014 Annual Meeting, Chicago, IL. May 2014 • Memorial Hospital Wellness Night at McCoy Paw Sox Stadium, 2011-2015 Community health awareness counselling and screening • Rhode Island State House Testimony Regarding Bill H-5158 05/2011 American Cancer Society – advocacy regarding tobacco control bill

Research support

Mentorship

16